Middle East & Africa NGS Market by Offering (Kits [Library Prep, QC, DNA Extraction], System) Type (Genome, Exome, Targeted), Application (Reproductive, Oncology, Infectious, Drug Discovery), Technology (SBS, Nanopore, Nanoball, SMRT Seq) – Forecast to 2031

The Middle East & Africa NGS Market was valued at $155 million in 2023. This market is expected to reach $356.5 million by 2031, from an estimated $170.7 million in 2024, at a CAGR of 11.1% during the forecast period 2024-2031.

Middle East & Africa NGS Market Size & Forecast

Next Generation Sequencing (NGS) is a genome sequencing technology usually used for research purposes and applied in clinical diagnostics. NGS determines the order of nucleotides in the entire genomes or targeted regions of DNA or RNA. It is used for various research and clinical applications such as disease diagnosis, prognosis, therapeutic decisions, follow-up of patients, drug discovery, biomarker research, and environmental testing. Also, its massive parallel sequencing capacity offers new opportunities for personalized or precision medicine.

The growth of the Middle East & Africa NGS market can be attributed to various factors, including the surge in genome sequencing programs, technological advancements in sequencing procedures, decreasing costs of genome sequencing, and a rise in cancer prevalence, and the expanding applications of NGS in cancer treatment and research. However, the high costs of NGS systems and consumables and the availability of alternative technologies restrain the market's growth.

The rising adoption of bioinformatics and genomic data management solutions, as well as collaborations and partnerships to support next-generation sequencing, are expected to create market growth opportunities. However, a lack of skilled professionals and a lack of standardization pose a significant challenge to the market's growth.

Click here to: Get Free Sample Pages of this Report

Surge in Genome Sequencing Projects, Driving the Market's Growth

With rapid advancements in NGS technology, various organizations & governments are actively undertaking initiatives for genomic sequencing projects. These initiatives aim to improve early disease diagnosis. Some of the initiatives are as follows:

• According to The National (a local daily newspaper), in March 2023, the UAE President launched the National genome strategy. This launch aims to map the DNA of every citizen to provide personalized care to every citizen in the country.

• the Qatar Genome Program (QGP), launched in 2015, completed the sequencing of 25,000 whole genomes in 2021 and is now in its largest “Phase 3”, with the aim to sequence 100,000 genomes by 2025.
• In October 2020, the Africa Centers for Disease Control and Prevention and the African Union Commission launched an initiative to expand genomics-based public health pathogen surveillance. This pathogen genomics initiative was launched with an investment of USD 100 million from its partners to expand NGS capabilities in the region.

Collaborations and Partnerships to Support Next-Generation Sequencing, Creating Market Growth Opportunities

Next Generation Sequencing (NGS) is a technology used to sequence the orientation of nucleotides in genetic material. This technology enables the sequencing of DNA or RNA more quickly and at a lower cost compared to Sanger sequencing. Continuous developments in NGS technology are revolutionizing the field of personalized medicine, genetic diseases, and clinical diagnostics by providing the capability to sequence multiple individuals with a variable genetic orientation simultaneously. Various organizations are focusing on partnerships, collaborations, and expansion to increase genetic testing and support next-generation sequencing. For instance:

• In January 2024, Guardant Health, Inc. (U.S.) partnered with Hikma Pharmaceuticals PLC (U.K.) to expand Guardant Health's portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring, and tumor mutation profiling for all solid cancers across the Middle East and North Africa (MENA). This partnership improved access to Guardant's next-generation sequencing (NGS) tests in the Middle East and North Africa.
• In May 2023, Pfizer Inc. (U.S.) collaborated with Thermo Fisher Scientific Inc. (U.S.) to improve the availability of NGS-based lung and breast cancer testing in over 30 countries across Latin America, Africa, the Middle East, and Asia.

Thus, increasing collaborations and partnerships among vendors are expected to accelerate the adoption of NGS technology in the Middle East & Africa.

Key Findings in the Middle East & Africa NGS Market Study:

Consumables Segment to Account for the Largest Share of the Market in 2024

Among the offerings, in 2024, the consumables segment is expected to account for the largest share of the Middle East & Africa NGS market. The increasing use of sequencing reagents and kits for diagnostic procedures has majorly attributed to the large share of this segment in the Middle East & Africa NGS market. Additionally, factors such as increasing genome mapping projects, rising preference for NGS-based diagnostic tests, and increasing awareness about the advantages of NGS for diagnostic and research purposes are supporting the growth of the segment.

Targeted Genome Sequencing Segment to Account for the Largest Share of the Market in 2024

Among sequencing types, in 2024, the targeted genome sequencing segment is expected to account for the largest share of the Middle East & Africa NGS market. Targeted genome sequencing significantly reduces the cost per sample over whole genome shotgun sequencing by enabling sequencing of only the desired regions of a genome. Furthermore, the early success of targeted sequencing methods has created a rapidly growing demand for targeted sequencing in areas such as cancer, human genetic disease, and the validation of genome-wide association studies. These factors have increased the adoption of targeted genome sequencing, contributing to the large market share of this segment.

Sequencing by Synthesis Segment to Account for the Largest Share of the Market in 2024

Among the technologies, in 2024, the sequencing by synthesis segment is expected to account for the largest share of the Middle East & Africa NGS market. The large share of this segment is primarily attributed to the high accuracy of this technology in DNA sequencing, its highest yield of error-free throughput, and the increasing incorporation of this technology in NGS products.

Research Applications Segment to Account for the Largest Share of the Market in 2024

Among the applications, in 2024, the research applications segment is expected to account for the largest share of the Middle East & Africa NGS market. The large market share of this segment is attributed to the rising adoption of sequencing-based tests in laboratories, growing research activities by pharmaceutical & biotechnology companies, increasing applications of NGS, growing demand for personalized medicines, and increasing availability of NGS instruments at lower costs are some of the major factors attributed to the large share of this segment in the NGS market.

Pharmaceutical & Biotechnology Companies Segment to Account for the Largest Share of the Middle East & Africa NGS Market in 2024

Among the end users, in 2024, the pharmaceutical & biotechnology companies’ segment is expected to account for the largest share of the Middle East & Africa NGS market. The large market share of this segment is attributed to factors such as the increasing adoption of advanced technologies for research purposes, increasing research for drug discovery with widening NGS applications, and the rising incidence of chronic diseases. For instance, according to GLOBOCAN, in 2022, 5,526 people were diagnosed with cancer in the United Arab Emirates. This number is projected to reach 7,328 by 2030. Further, in 2022, 28,113 people were diagnosed with cancer in Saudi Arabia. This number is projected to reach 39,900 by 2030.

Saudi Arabia to Account for the Largest Market Share in 2024

In 2024, Saudi Arabia is expected to account for the largest share of the Middle East & Africa NGS market. Saudi Arabia’s significant market share can be attributed to the growing adoption of NGS technology among healthcare professionals for the treatment of diseases and an increasing number of sequencing projects such as the Saudi Human Genome Programme, The Saudi Biobank, and Majeen.

Middle East & Africa NGS Market: Competitive Analysis

The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market players over the past three to four years. The key players profiled in the Middle East & Africa NGS market report are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), 10X Genomics, Inc. (U.S.), and Pacific Biosciences of California Inc. (U.S.).

Middle East & Africa NGS Market Report Summary:

Key questions answered in the report: